MA40982A - Formulation de bille pharmaceutique comprenant du fumarate de diméthyle - Google Patents

Formulation de bille pharmaceutique comprenant du fumarate de diméthyle

Info

Publication number
MA40982A
MA40982A MA040982A MA40982A MA40982A MA 40982 A MA40982 A MA 40982A MA 040982 A MA040982 A MA 040982A MA 40982 A MA40982 A MA 40982A MA 40982 A MA40982 A MA 40982A
Authority
MA
Morocco
Prior art keywords
pharmaceutical
dimethyl fumarate
formulation including
including dimethyl
ball formulation
Prior art date
Application number
MA040982A
Other languages
English (en)
Inventor
Shyam B Karki
Cheuk-Yui Leung
Yiqing Lin
Andrea Trementozzi
Kalyan Vasudevan
Jin Xu
Peter Zawaneh
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA40982A publication Critical patent/MA40982A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2873—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA040982A 2014-11-19 2015-11-18 Formulation de bille pharmaceutique comprenant du fumarate de diméthyle MA40982A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462081889P 2014-11-19 2014-11-19

Publications (1)

Publication Number Publication Date
MA40982A true MA40982A (fr) 2017-09-26

Family

ID=54705913

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040982A MA40982A (fr) 2014-11-19 2015-11-18 Formulation de bille pharmaceutique comprenant du fumarate de diméthyle

Country Status (13)

Country Link
US (1) US11197842B2 (fr)
EP (1) EP3220898A1 (fr)
JP (2) JP6843748B2 (fr)
KR (1) KR20170086063A (fr)
CN (2) CN113521029A (fr)
AU (1) AU2015349896B2 (fr)
CA (1) CA2967647A1 (fr)
EA (1) EA039157B1 (fr)
HK (1) HK1244214A1 (fr)
IL (1) IL252116B (fr)
MA (1) MA40982A (fr)
MX (1) MX2017006562A (fr)
WO (1) WO2016081676A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016194004A1 (fr) 2015-06-01 2016-12-08 Sun Pharmaceutical Industries Ltd. Compositions pharmaceutiques de fumarate de diméthyle
CA3013472A1 (fr) * 2016-02-11 2017-08-17 Biogen Ma Inc. Formulations pharmaceutiques de billes comprenant du dimethylfumarate
CN110636838A (zh) 2017-06-23 2019-12-31 阿尔米雷尔有限公司 包含反丁烯二酸二甲酯的药物组合物
KR20250042852A (ko) 2018-01-12 2025-03-27 (주) 메티메디제약 만성 염증성 질환의 치료 방법
TR201818307A2 (tr) * 2018-11-30 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇meti̇l fumarat i̇çeren bi̇r kompozi̇syon
PH12021552668A1 (en) * 2019-05-31 2022-09-19 Curacle Co Ltd Enteric tablet containing dimethyl fumarate
WO2022203432A1 (fr) * 2021-03-25 2022-09-29 주식회사 큐라클 Composition pharmaceutique contenant du fumarate de diméthyle en tant que principe actif, présentant un paramètre pharmacocinétique spécifique

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
ES2157731B1 (es) * 1998-07-21 2002-05-01 Liconsa Liberacion Controlada Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
WO2002085335A1 (fr) * 2001-04-18 2002-10-31 Nostrum Pharmaceuticals Inc. Nouvel enrobage de composition pharmaceutique a liberation lente
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
SI1799196T1 (sl) * 2004-10-08 2016-10-28 Forward Pharma A/S Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline
EP2564839B1 (fr) 2009-01-09 2016-05-11 Forward Pharma A/S Formule pharmaceutique comportant un ou plusieurs esters d'acide fumarique dans une matrice érosive
EP2379062A1 (fr) 2009-01-09 2011-10-26 Forward Pharma A/S Composition pharmaceutique comprenant un ou plusieurs esters d'acide fumarique
WO2010099508A1 (fr) * 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Compositions pharmaceutiques orales à libération prolongée de 3-hydroxy-n-méthylmorphinane et procédé d'utilisation
DK2533634T3 (en) * 2010-02-12 2016-01-25 Biogen Ma Inc NEURO PROTECTIVE demyelinating diseases
RU2014125430A (ru) * 2011-11-24 2015-12-27 Синтон Бв Контролируемое высвобождение частиц, содержащих диметилфумарат
CA2862885C (fr) * 2012-02-07 2020-06-02 Biogen Ma Inc. Compositions pharmaceutiques contenant du fumarate de dimethyle
EP2692343A1 (fr) * 2012-08-03 2014-02-05 Forward Pharma A/S Polythérapie pour le traitement de la sclérose en plaques
US20140171504A1 (en) 2012-12-14 2014-06-19 Georgia Regents Research Institute, Inc. Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
US20140178468A1 (en) * 2012-12-24 2014-06-26 Ranbaxy Laboratories Limited Multiparticulate extended-release composition of mesalamine
US20140275250A1 (en) 2013-03-15 2014-09-18 Xenoport, Inc. Methods of Administering Monomethyl Fumarate
AU2014314231A1 (en) * 2013-08-26 2016-03-03 Fwp Ip Aps Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
WO2015105757A1 (fr) * 2014-01-07 2015-07-16 Biogen Ma Inc. Fumarate de diméthyle pour traiter une sclérose en plaques
CN104027311A (zh) * 2014-05-09 2014-09-10 万特制药(海南)有限公司 一种含有富马酸二甲酯的肠溶缓释微丸

Also Published As

Publication number Publication date
AU2015349896A1 (en) 2017-05-25
IL252116B (en) 2022-08-01
HK1244214A1 (zh) 2018-08-03
EA201791113A1 (ru) 2017-10-31
CN113521029A (zh) 2021-10-22
WO2016081676A1 (fr) 2016-05-26
IL252116A0 (en) 2017-07-31
MX2017006562A (es) 2018-02-19
US11197842B2 (en) 2021-12-14
JP2021088586A (ja) 2021-06-10
EA039157B1 (ru) 2021-12-13
JP2017534668A (ja) 2017-11-24
CN107205937A (zh) 2017-09-26
KR20170086063A (ko) 2017-07-25
US20180153845A1 (en) 2018-06-07
CA2967647A1 (fr) 2016-05-26
AU2015349896B2 (en) 2021-04-29
JP6843748B2 (ja) 2021-03-17
EP3220898A1 (fr) 2017-09-27

Similar Documents

Publication Publication Date Title
DK3494962T3 (da) Flydende inhalationsformulering omfattende RPL554
EP3679924C0 (fr) Formulation comprenant des particules
MA42844A (fr) Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1
MA43705A (fr) Formulation pharmaceutique
DK3634377T3 (da) Farmaceutisk formulering
EP3300502A4 (fr) Préparation comprenant des arabinoxylo-oligosaccharides
IL253570B (en) Pharmacy composition
IL266537A (en) pharmaceutical preparation
DK3193840T3 (da) Arimoclomol-formulering
PT3212237T (pt) Formulação de metotrexato
IL253177A0 (en) Pharmacy preparation
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
IL252116A0 (en) Pharmaceutical granule formulations containing dimethyl fumarate
EP3383371A4 (fr) Formulation pharmaceutique
EP3638322A4 (fr) Formulation de décontamination
IL258744B (en) An improved herbicidal formulation
EP3389633A4 (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
MA44010A (fr) Formulations pharmaceutiques de billes comprenant du diméthylfumarate
CL2016002705A1 (es) Formulación agroquímica
ZA201807851B (en) Pharmaceutical formulation
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
BR112016027580A2 (pt) Formulação de ceritinib
DK3601277T3 (da) Farmaceutisk formulering
MA40990A (fr) Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle
EP3471546A4 (fr) Formulation insecticide